Pfizer Q3 2024 Earnings Analysis

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown where we turn complex corporate calls into clear insights. I'm Alex, and with me as always is Jordan.**JORDAN**: Hey everyone! Today we're diving into Pfizer's Q3 2024 earnings, and wow - this was a solid quarter that really shows the pharma giant is hitting its stride post-pandemic.**ALEX**: Before we jump in, I need to share our mandatory disclaimer - this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN**: Absolutely. Now Alex, let's talk numbers because Pfizer really delivered here.**ALEX**: They did! Total revenue came in at $17.7 billion, which represents an impressive 32% operational growth year-over-year. But here's what I found interesting - it wasn't just COVID products driving this growth.**JORDAN**: Right, and that's crucial context. PAXLOVID contributed $2.7 billion and COMIRNATY added $1.4 billion, but their non-COVID business also showed robust performance with $13.6 billion in revenue - that's 14% operational growth on its own.**ALEX**: That non-COVID growth is really the story here. It shows their underlying business is healthy and growing, which addresses one of the biggest concerns investors have had about Pfizer - what happens when COVID revenue normalizes?**JORDAN**: Exactly. And speaking of normalization, CEO Albert Bourla made some fascinating comments about COVID becoming "normal business" now. He pointed out that PAXLOVID usage patterns in 2024 are almost identical to 2023 - 4.9 million patients treated through Q3 this year versus 5.2 million last year.**ALEX**: That predictability is huge for investors. Bourla even said they'll stop separating COVID from non-COVID business because "it's Pfizer business." But let's talk about their star performers outside of COVID.**JORDAN**: Oncology was the standout with 31% year-over-year growth. XTANDI grew 28%, TALZENNA surged 77%, and they're seeing great momentum with newer launches like PADCEV, which has become the most prescribed first-line treatment for advanced bladder cancer.**ALEX**: The TALZENNA data was particularly exciting. They announced that TALZENNA combined with XTANDI showed statistically significant overall survival benefit in prostate cancer patients - becoming the first and only such combination to do so. That's huge for a cancer that's the second most common in men.**JORDAN**: And don't sleep on their pipeline. They've got multiple Phase III trials starting, including their CDK4 inhibitor for breast cancer and several next-generation ADCs for lung cancer. The Seagen acquisition is really paying dividends here.**ALEX**: Speaking of Seagen, that integration seems to be going smoothly. They retained the vast majority of Seagen employees and the legacy Seagen products contributed $854 million in Q3 alone, with PADCEV generating over $400 million.**JORDAN**: Now, we can't ignore the elephant in the room - the activist investor situation with Starboard Value.**ALEX**: Bourla addressed this head-on, which I appreciated. He acknowledged they met with Starboard two weeks ago and said while they agree with some points, they have "vastly different views on many others." Particularly around capital deployment and business development.**JORDAN**: His response was pretty measured. He defended deals like Seagen and BioNTech as transformational, and pointed out they've been executing a five-point strategic plan since January that's showing results. Three consecutive quarters of revenue growth, successful cost reduction programs, strong pipeline advancement.**ALEX**: The cost management story is compelling too. They're on track to deliver $4 billion in net cost savings from their realignment program and expect $1.5 billion in manufacturing savings by 2027.This episode includes AI-generated content.